Pharma Pulse 8/2/24: Overcoming Challenges to Drive Digital Customer Engagement, Mental Health Leaves of Absence Continue to Proliferate & more
The latest news for pharma industry insiders.
Personalizing Pharma: Overcoming Challenges to Drive Digital Customer Engagement
As HCPs continue to face time constraints and information overload, delivering relevant and personalized content becomes increasingly critical.
Five Ways Cancer Care Teams Can Best Utilize the Expertise of Pharmacists
Pharmacists' roles in community-based cancer centers are expanding, with a more significant role in managing complex treatment regimens, ensuring comprehensive patient care, navigating drug shortages, and collaborating with multidisciplinary teams to enhance patient outcomes and streamline health care operations.
Meta’s earnings calm A.I. jitters
Another tech giant has run the gantlet of investor worries about the costs of commercializing artificial intelligence — except that this one passed with flying colors.
ComPsych® Corporation has released new data that shows mental health related leaves continue to skyrocket among U.S. workers. A sample analysis of ComPsych’s absence book of business, which covers more than six million people, found that in the first quarter of 2024, more than one in ten (11%) of all leaves of absence were due to mental health. This represents a 22% increase in mental health leaves versus those taken in the first quarter of 2023. This trend is being driven by female workers, who accounted for 69% of all mental health leaves of absence in 2023, and 71% of all mental health leaves in the first quarter of 2024.
Mistrust among drug discount program stakeholders “could lead to an even greater level of dysfunction related to drug discounts,” warns Kalderos Chief Strategy Officer Daryl Todd in a recent column published by Pharmaceutical Commerce Magazine.
Outlining the growing noncompliance challenges facing 340B and other drug discount programs, Daryl writes that “multiple claims for a single drug dispense can add up to millions of dollars in noncompliant claims for drug manufacturers.”
The key to remedying this problem, he argues, “revolves around greater collaboration between critical stakeholders, including drug manufacturers, CEs, and state Medicaid agencies.” “With greater collaboration and better alignment of incentives,” Daryl concludes, “the industry can do better for patients who need access to low-cost and potentially life-saving drugs.”
You can read Daryl’s column, which includes three recommendations for improving collaboration among drug discount stakeholders here: https://lnkd.in/gYMaiZCk
#DrugDiscounts #DrugDiscountNoncompliance #340B #pharmaceutical
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
